Scilex Holding Company
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a SCLX research report →
Companywww.scilexholding.com
Scilex Holding Company, a biopharmaceutical company, focuses on developing and commercializing non-opioid management products for the treatment of acute and chronic pain. Its commercial product is ZTlido 1. 8%, a prescription lidocaine topical product for the relief of neuropathic pain related with post-herpetic neuralgia, which is a form of post-shingles nerve pain.
- CEO
- Henry H. Ji
- IPO
- 2021
- Employees
- 115
- HQ
- Palo Alto, CA, US
Price Chart
Valuation
- Market Cap
- $51.03M
- P/E
- -0.10
- P/S
- 1.51
- P/B
- -0.16
- EV/EBITDA
- -0.39
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 54.96%
- Op Margin
- -817.05%
- Net Margin
- -1239.37%
- ROE
- 189.09%
- ROIC
- 218.94%
Growth & Income
- Revenue
- $30.25M · -46.54%
- Net Income
- $-358,734,000 · -392.72%
- EPS
- $-36.48 · -87.75%
- Op Income
- $-272,304,000
- FCF YoY
- -80.97%
Performance & Tape
- 52W High
- $34.27
- 52W Low
- $4.20
- 50D MA
- $7.46
- 200D MA
- $13.82
- Beta
- 1.79
- Avg Volume
- 58.66K
Get TickerSpark's AI analysis on SCLX
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Apr 17, 26 | Ma Stephen Hoi | buy | 650,000 |
| Apr 16, 26 | Ji Henry | buy | 3,250,000 |
| Apr 17, 26 | Ji Henry | sell | 650,000 |
| Dec 26, 25 | Scilex Holding Co | sell | 3,689,016 |
| Dec 29, 25 | Scilex Holding Co | sell | 7,310,984 |
| Dec 30, 25 | Scilex Holding Co | sell | 9,657,300 |
| Oct 8, 25 | Wu Yue Alexander | other | 20,000 |
| Oct 8, 25 | Ma Stephen Hoi | other | 60,000 |
| Oct 8, 25 | Chun Jay | other | 20,000 |
| Oct 8, 25 | Ji Henry | other | 120,000 |
Our SCLX Coverage
We haven't published any research on SCLX yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate SCLX Report →